-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzamend Neuro Says Massachusetts General Ends AL001 Bipolar Disorder Trial Agreement

PUBT·11/17/2026 21:33:26
Listen to the news
Alzamend Neuro Says Massachusetts General Ends AL001 Bipolar Disorder Trial Agreement
  • Alzamend Neuro's Massachusetts General Hospital partner terminated the AL001 Phase II bipolar disorder trial agreement on November 11, 2026, following a pause.
  • October 15 FDA feedback questioned whether the planned trials could provide sufficient evidence of effectiveness to support a drug application.
  • The proposed revised development plan would end Phase II trials of AL001 and move directly to Phase III in bipolar disorder.
  • A planned FDA meeting would address the revised strategy, with feedback expected by the end of the second quarter of 2027.
  • The completed healthy-subject trial remains unaffected; final results are scheduled for release in December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-014504), on November 17, 2026, and is solely responsible for the information contained therein.